Trend in blood serum levels of light and heavy chains of neurofilaments in infants with spinal muscular atrophy against background of the use of gene therapy
Authors:
- Дарья Андреевна ФисенкоДФДарья Андреевна Фисенко
- Людмила Михайловна КузенковаЛКЛюдмила Михайловна Кузенкова
- Алексей Львович КуренковАКАлексей Львович Куренков
- Елена Леонидовна СемикинаЕСЕлена Леонидовна Семикина
- Евгения Владимировна УвакинаЕУЕвгения Владимировна Увакина
- Владислав Владимирович ЧерниковВЧВладислав Владимирович Черников
- Ольга Владимировна КурбатоваОКОльга Владимировна Курбатова
- Tatiana M. KomyaginaTKTatiana M. Komyagina
- Matvei V. KonyashinMKMatvei V. Konyashin
- София Георгиевна ПоповичСПСофия Георгиевна Попович
Open Access
- 30 April 2025
- journal article
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 6 (1) , 26-36
Abstract
Introduction. Determination of neurofilaments (NF) levels in blood serum and CSF in children with spinal muscular atrophy (SMA) may be a promising biomarker of the severity and course of the disease, as well as a way of assessing the effectiveness of pathogenetic therapy. The aim of the study was to determine the blood serum NF levels of in 0–24 months infants with SMA type I at the presymptomatic stage of the disease before and after gene therapy with onasemnogene abeparvovec (OA). Materials and methods. The study included one hundred fifty five 0–24 months infants including 76 neurologically healthy children (group II), as well as 79 patients with SMA from group I (subgroup Ia — 44 infants with SMA type I, Ib — 35 infants at the presymptomatic stage of the disease) with a diagnosis of SMA. The majority of infants with type I SMA (subgroup Ia) had 2 copies of the SMN2 gene (n = 43; 97.7%), while infants from subgroup Ib (asymptomatic patients) had 3 copies (n = 31; 88.6%). Results. The values of NF light and heavy chains in infants from group I were obtained before and after 3–6, 7–12, and 13–24 months after gene therapy with OA. The NF light chains level in the Ia subgroup before treatment was significantly higher than in the Ib subgroup (p < 0.001) and higher than in the control group (p < 0.001). The serum level of NF heavy chains in the Ia subgroup before treatment was also significantly higher than in the control group. In the Ia subgroup, there was a significant decrease (p < 0.01) in serum NF light chains 3–6 months after gene therapy (Me [Q1; Q3] — 22.97 [6.00; 48.54]) compared with the same indices before treatment (6.0 [5.92; 7.78]). Subsequently, after 7–12 months (6.15 [5.15; 7.30]) and 13–24 months (6.0 [5.7; 6.6]), stabilization of Me values was noted with a decrease in interquartile ranges. In the Ib subgroup, there was also a significant decrease (p < 0.01) in serum NF light chains levels 3–6 months after OA gene therapy (6.0 [6.00; 7.25]) compared with these indices before treatment (6.0 [6.00; 31.43]). Conclusion. Determination of the blood serum NF light and heavy chains levels in SMA patient before and after gene therapy can be regarded as a marker of the severity of the disease and the effectiveness of treatment.Keywords
This publication has 42 references indexed in Scilit:
- Usefulness of serum neurofilament light in the assessment of neurologic outcome in the pediatric population: a systematic literature reviewEuropean Journal of Pediatrics, 2023
- Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in ChildrenMovement Disorders, 2022
- Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy childrenAnnals of Clinical and Translational Neurology, 2021
- Ratio and index of Neurofilament light chain indicate its origin in Guillain‐Barré SyndromeAnnals of Clinical and Translational Neurology, 2020
- Neurofilaments in disease: what do we know?Current Opinion in Neurobiology, 2020
- Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersenJournal of Neurology, 2019
- Serum neurofilament heavy chains as early marker of motor neuron degenerationAnnals of Clinical and Translational Neurology, 2019
- Neurofilament as a potential biomarker for spinal muscular atrophyAnnals of Clinical and Translational Neurology, 2019
- Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral SclerosisJAMA Neurology, 2017
- Direct ELISA2015